Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04688151 | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | completed | Phase 1 | 22 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01352962 | Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03418480 | HARE-40: HPV Anti-CD40 RNA vaccinE(HARE-40) | completed | Phase 1 / Phase 2 | 32 | University of SouthamptonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05249426 | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT06236425 | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01279694 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)(CARMYSAP) | completed | Phase 1 / Phase 2 | 72 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients(OAsIs) | completed | Phase 1 / Phase 2 | 48 | Nantes University HospitalOTHER | 2 | Sep 14, 2026 | clinicaltrials |
| NCT03042468 | Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | completed | Phase 1 / Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04084067 | Indocyanine Green (ICG) Guided Tumor Resection | completed | Phase 1 | 215 | St. Jude Children's Research HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04547062 | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)(Tocilam) | completed | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT05821231 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma(MEDISARC-SBRT) | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04896697 | Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 125 | Xilio Development, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study. | completed | Phase 1 / Phase 2 | 125 | Sun Yat-sen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies(ARC-8) | completed | Phase 1 | 196 | Arcus Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05320809 | Study of 3D189 in Patients With Hematologic Malignancies | completed | Phase 1 | 16 | 3D MedicinesINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06076291 | An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors(CSG-1827-101) | completed | Phase 1 | 19 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06167486 | SG2918 For Advanced Malignant Tumors | completed | Phase 1 | 17 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03674567 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | completed | Phase 1 / Phase 2 | 323 | RAPT Therapeutics, Inc.INDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT05282459 | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | completed | Phase 1 / Phase 2 | 17 | Tian Yi ZhangOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802977 | Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia | completed | Phase 1 | 10 | University of California, DavisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 35 | Inovio PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04276493 | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | completed | Phase 1 / Phase 2 | 71 | BeiGeneINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04330820 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)(RELAX) | completed | Phase 1 / Phase 2 | 55 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04530916 | Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women(WB2020) | completed | Phase 1 / Phase 2 | 58 | Colorado State UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05721846 | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer(CheckVAC) | completed | Phase 1 | 20 | Inna Chen, MDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL(TACTAL) | completed | Phase 1 | 36 | Baylor College of MedicineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | completed | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03021460 | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT01445509 | Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04201873 | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | completed | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04868344 | A Study of MRG003 in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT01582191 | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03388619 | Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT05479812 | Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | completed | Phase 1 | 156 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | completed | Phase 1 | 30 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03258593 | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials